Phase 3 Type 2 Diabetes Trial, Recruiting NCT07662213 Sponsor: AstraZeneca Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 3 Type 2 Diabetes Trial, Recruiting

NCT07662213
Recruiting Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Type 2 Diabetes for at least 90 days before the screening appointment
  • People whose Type 2 Diabetes is not well controlled through lifestyle changes alone, or who have been on a stable diabetes medication routine
  • People whose blood sugar control levels (measured by a test called HbA1c) fall within a specific range — between 7% and 10.5% (confirm with trial site)
  • People who have at least one existing heart or blood vessel condition (such as coronary heart disease, peripheral artery disease, stroke-related disease, or a moderate level of heart failure), or who have two or more risk factors for heart or blood vessel problems
  • People with a body mass index (a measure of body weight relative to height) of 23 or above at screening
  • People whose body weight has been stable for at least 90 days before screening

Who may not be able to join:

  • People who have Type 1 Diabetes, a rare or inherited form of diabetes, or a history of a serious diabetes-related emergency such as ketoacidosis or hyperosmolar coma
  • People who are currently receiving, or are expected to receive, treatment for a diabetes-related eye condition affecting the retina or the central part of the eye
  • People who have had more than one serious low blood sugar episode in the 180 days before screening, or who have difficulty recognising the warning signs of low blood sugar
  • People with a significant condition affecting the upper digestive system, or who regularly take medication that affects how the stomach moves or empties
  • People with a history of inflammation of the pancreas (either short-term or long-term)
  • People with severe heart failure (at the most serious level, known as NYHA Class IV)
  • People with a personal or family history of a specific type of thyroid cancer (medullary thyroid cancer) or a related inherited condition called multiple endocrine neoplasia type 2

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 1-877-240-9479

Australian sites

Research Site, Botany,
Research Site, East Toowoomba,
Research Site, Fitzroy,
Research Site, Heidelberg Heights,
Research Site, Kingswood,
Research Site, Melbourne,
Research Site, Parkville,
Research Site, St Leonards,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
6 July 2026
Est. completion
23 May 2028

Where this trial is recruiting

🇦🇷 Argentina 🇦🇺 Australia 🇧🇷 Brazil 🇧🇬 Bulgaria 🇨🇦 Canada 🇨🇳 China 🇩🇪 Germany 🇭🇺 Hungary 🇮🇹 Italy 🇯🇵 Japan 🇵🇱 Poland 🇰🇷 South Korea 🇹🇼 Taiwan 🇬🇧 United Kingdom 🇺🇸 United States

8 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Change from baseline in Hemoglobin A1c (HbA1c)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov